Posted on 06/04/2009 in Pharmaceutical Company Product News Shire will take all necessary actions to protect its patents, it has asserted.
This statement came after the biopharmaceutical company announced it had filed a lawsuit against Natco for breach of two of its exclusive rights.
Patent numbers 5,968,976 and 7,381,428 are affected and the grievance was in response to an Abbreviated New Drug Application the latter submitted to the Food and Drug Administration (FDA).
Natco's request was to market and sell generic versions of Shire's 500mg, 750mg and 1g Fosrenol products.
Depending on which happens first, the FDA must avoid making a decision on the application for either 30 months, or until the district court asserts whether the patents are invalid or not.
Shire remarked it would continue to evaluate its position throughout the court proceedings.
"[We have] a robust patent estate and is confident that it will protect the fosrenol franchise," it commented.
Last week, the business agreed to co-promote Vyvanse with GlaxoSmithKline to treat attention-deficit hyperactivity disorder in adults.
Under the terms of the agreement, 600 sales representatives from the latter will assist the former to sell the product.Other news stories from 06/04/2009
Read more in the Zenopa News Archive
How this news is generated
|
